Prihlásiť sa Zaregistrujte sa zadarmo

% krátkych akcií spoločnosti Abeona Therapeutics Inc

Aká je hodnota metriky % krátkych akcií spoločnosti Abeona Therapeutics Inc?

Hodnota metriky % krátkych akcií spoločnosti Abeona Therapeutics Inc je 6.01%

Aká je definícia metriky % krátkych akcií?



% krátkych akcií (Short % of float) je počet akcií predaných na krátko v porovnaní so všetkými akciami v obehu (float) vyjadrený v percentách.

Short percentage of float, or short interest ratio, is calculated by taking the total amount of shares shorted and dividing it by the total amount of shares available for trade. It is an indirect metric of investor sentiment. When short percentage of float is high, above 40%, it implies company investors hope shares will decline in value. The percentage is used by both fundamental and technical traders to identify trends. The short percentage of float can also be calculated for entire exchanges to determine the sentiment of the market as a whole. If it is high of around five or greater for an exchange, this can be taken as a bearish signal, and vice versa.

% krátkych akcií spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Abeona Therapeutics Inc

Čomu sa venuje spoločnosť Abeona Therapeutics Inc?

abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t

Firmy s metrikou % krátkych akcií podobnou spoločnosti Abeona Therapeutics Inc